Research programme: cancer therapeutics - Arch BioPartners/University of ColoradoAlternative Names: GH501a
Latest Information Update: 10 Jul 2016
At a glance
- Originator University of Colorado Foundation
- Developer Arch Biopartners; University of Colorado Foundation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Sep 2011 A lead compound, GH 501a, is selected for further development